Amarin Corp Ads (AMRN)
$6.72 0.08 (1.20%)
19:59 EDT AMRN Stock Quote Delayed 30 Minutes
Previous Close $6.72
Market Cap 1.97B
PE Ratio -
Volume (Avg. Vol.) 3.32M
Day's Range 6.57 - 6.74
52-Week Range 3.95 - 26.12
Dividend & Yield N/A (N/A)
AMRN Stock Predictions, Articles, and Amarin Corp Ads News
- From InvestorPlace
- From the Web
Although the FDA approval is nice, fundamentally, Amarin stock is banking on a fish oil drug. Given its similarity to OTC counterparts, that doesn’t bode well for stakeholders.
Amarin is expecting an increase in sales for its fish-oil derived drug Vascepa. But investors are questioning if Amarin may be an M&A target.
Last week's slide very could be a sign that plenty of investors are already dumping Amarin following the Food and Drug Administration's (FDA) approval of the Vascepa drug, a fish oil-based treatment used to reduce a patient's chance of falling victim to major cardiovascular issues, such as heart attacks and strokes.
Amarin stock is at sky high levels assuming all the good news. The FDA drug approval was anticipated and the AMRN stock price had implied it already.
Short sellers have targeted AMRN and the Amarin stock price is quite undervalued, making the shares quite attractive for long-term investors.
What does the FDA's recent approval of Vascepa mean for Amarin stock? Is the company really a target for buyout offers?
Amarin is targeting a huge market, and its main drug -- Vascepa -- is likely to be expanded in its coverage. Here’s a look at what’s ahead for the stock.
An FDA approval unquestionably is good news for Amarin. But valuation remains a concern.
Thanks to the effective cardiovascular drug Vascepa, Amarin stock has enjoyed an outsized performance so far this year. However, over the horizon stands big pharmaceutical competitors that are ready to spoil the party.
Amarin stock is set to move higher on a potential label expansion. But does this mean that the drug will perform well in the market?
Options trading was heating up in Amarin, Disney and Facebook stock on Tuesday. Here’s what the data suggests moving forward.
PayPal, Disney, Amarin, Overstock and the S&P 500 ETF were our top stock trades for Wednesday. Here's a look at the charts now.
This morning, I'm recommending a bullish call option on Amarin Corporation plc (NASDAQ:AMRN), the biopharmaceutical company.
These are stocks with extremely high potential returns. We are talking about upside potential of over 100%. And that’s not just according to my wild calculations. That’s according to the analysts covering these stocks.
Uncertainty is a constant risks for biotech stocks. Which ones matter? Some are down so much investors cannot ignore them now.
From Simply Wall St
Today we will run through one way of estimating the intrinsic value of The Western Union Company (NYSE:WU) by taking the forecast future cash flows of the company and discounting<div><a class="permalink" href="https://simplywall.st/stocks/us/software/nyse-wu/western-union/news/an-intrinsic-calculation-for-the-western-union-company-nysewu-suggests-its-40-undervalued/">Read More...</a></div>
Navellier RatingsPowered by Portfolio Grader